The synergy between paclitaxel and ABT-263 for the activation of apoptosis clearly demonstrated that ABT-263 can counteract Bcl-xl in paclitaxel-sensitive and paclitaxel-resistant prostate cancer cells. Here, BCL2L1 is linked to prostate carcinoma.